GlassScriptPhysician profile
Jennifer Ferree
NPI 1992909196
$9,136.29
in general payments reported to CMS, 2019-2025
23 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,217 · 2022: $1,260 · 2023: $1,446 · 2024: $2,960 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Consulting Fee: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.22 |
| Consulting Fee | $1,092.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $4,214.45 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $745.10 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $587.29 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Amgen INC. | $395.96 | 2024-2025 | Blincyto, Blincyto |
| Incyte Corporation | $344.71 | 2021-2025 | Niktimvo |
| Seagen INC. | $302.37 | 2021-2023 | Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $230.64 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $228.90 | 2024-2025 | |
| Sobi, INC | $227.90 | 2023-2024 | |
| Y-Mabs Therapeutics, INC. | $223.99 | 2024-2025 | Danyelza |
| Emmaus Medical, INC. | $214.27 | 2023-2024 | Endari |
| Alexion Pharmaceuticals, INC. | $189.45 | 2022-2025 | Koselugo |
| Chiesi USA, INC. | $125.00 | 2024 | Ferriprox |
| Celgene Corporation | $124.87 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $121.82 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $117.21 | 2025 | Gomekli |
| Global Blood Therapeutics, INC. | $116.79 | 2022 | |
| Genentech USA, INC. | $113.53 | 2023 | Tecentriq |
| Syndax Pharmaceuticals, INC. | $109.68 | 2025 | Revuforj |
| Bayer Healthcare Pharmaceuticals INC. | $106.19 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $105.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2022 | |
| Pfizer INC. | $92.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ferree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.